About us

GY Life Sciences Co., Ltd. was founded in April 2022, based on technology developed at the Korea Institute of Science and Technology in Seoul, Korea. The company's mission is to pioneer the development of small-molecule therapeutic compounds for challenging-to-treat diseases.

SMDRM (Small Molecule Driven Regenerative Medicine) technology, the flagship platform of GY Life Sciences, has empowered the discovery of Repurinol, a small molecular compound with the remarkable ability to regenerate healthy and original tissue from damaged and diseased tissue.

Repurinol has exhibited remarkable therapeutic effectiveness when applied to severe itching, various inflammatory skin lesions, and wounds in human skin. What sets this efficacy apart is Repurinol's unique ability to adeptly manage multiple pathological symptoms associated with a range of difficult-to-treat skin diseases. This distinctive characteristic stems from the compound's capacity to induce the regeneration of healthy tissue within the affected areas.

GY Life Sciences has successfully developed five commercial topical creams featuring Repurinol. These products offer relief to individuals grappling with various chronic skin conditions, such as severe itching, different forms of dermatitis, inflammatory lesions, as well as wounds resulting from burns or pressure ulcers, among others. It is worth noting that chronic skin symptoms can be distressing and severely impact one's quality of life. Unfortunately, existing treatment options often fall short of expectations. The innovative products from GY Life Sciences, however, are poised to address this significant unmet need for challenging-to-treat skin conditions.

GY Life Sciences is steadfast in its commitment to advancing the SMDRM (Small Molecule Driven Regenerative Medicine) platform technology for the discovery of novel treatment approaches for cancer and inflammatory disorders characterized by tissue fibrosis.

Research & Development

SMDRM (Small Molecule Driven Regenerative Medicine) technology and Repurinol

Regenerative medicine is currently a subject of active research, representing a promising future medical technology aimed at addressing incurable diseases. The primary focus of regenerative medicine studies revolves around the utilization of stem cells or the replacement of organs derived from animals. Nonetheless, their clinical applications remain in the early stages due to numerous challenging obstacles.

In contrast to these conventional approaches, GY Life Sciences has pioneered the development of SMDRM (Small Molecule Driven Regenerative Medicine) as its proprietary platform technology. This innovative concept in regenerative medicine entails the discovery of small-molecule compounds capable of orchestrating controlled wound healing responses within the pathological tissue or organs afflicted by hardly-treatable diseases. The application of these compounds facilitates the regeneration of normal and healthy tissue from the diseased counterpart. Leveraging this platform technology, GY Life Sciences has successfully identified "Repurinol," a small-molecule compound with the capacity to regenerate damaged tissue.

When a tissue or organ in our body is exposed to internal or external stimuli and becomes damaged, whether the damage is large or small, the natural wound healing process is initiated promptly. This reaction is intended to regenerate the original healthy tissue by repairing the damage. It comprises a series of intrinsic multi-cellular responses that naturally occur in every tissue of our body upon injury.

However, a significant challenge arises from the fact that these multi-cellular reactions often tend to become overly aggressive and persist longer than necessary, much like the principles of a fire alarm system applied to disaster management in our society. The continuous and excessive wound healing responses disrupt the normal tissue remodeling process and, conversely, contribute to the accumulation of various pathological mechanisms within the tissue. This overactive wound healing process fundamentally underlies a substantial number of degenerative and difficult-to-treat diseases.

The small molecules derived from our SMDRM (Small Molecule Driven Regenerative Medicine) technology play a crucial role in soothing these excessive and uncontrolled wound healing reactions that occur in the pathological lesions of hardly-treatable and degenerative diseases. As a result, the pathological tissue is able to activate its intrinsic regenerative capacity, leading to a healing effect on the affected tissue.

This pathological mechanism is most prominently observed in skin tissue since the skin is constantly exposed to a wide range of stimuli from the external environment more than any other tissue. Consequently, we have applied Repurinol to address the symptoms and lesions associated with challenging-to-treat skin disorders.

Development of topical products incorporating Repurinol and their application to a multitude of symptoms and lesions of hardly-curable skin diseases

GY Life Sciences has developed a topical formulation that enhances the transdermal penetration of Repurinol. This breakthrough has led to the creation of a range of topical products designed for various skin disorders. These products have demonstrated significant efficacy distinctions when compared to commonly used treatments like moisturizing creams or steroid creams. Notably, individuals who have endured chronic skin conditions for extended periods have expressed high levels of satisfaction.

Repurinol has exhibited remarkable versatility and a broad spectrum of effectiveness. It has been shown to suppress inflammatory symptoms associated with various dermatitis conditions, swiftly alleviate severe itching, promote the regeneration of damaged skin barrier structures, reduce the risk of pressure ulcers, and inhibit scar formation, among other benefits. This exceptional profile sets Repurinol cream apart from other topical products.

The rapid and long-lasting relief from severe itching provided by Repurinol cream addresses a significant unmet need for individuals seeking dermatological care. Furthermore, Repurinol cream effectively manages diverse dermatitis conditions, even those resistant to steroidal creams. Importantly, prolonged use of Repurinol cream does not result in adverse side effects, a notable advantage over steroidal creams.

One of Repurinol's key attributes is its ability to stimulate the recovery of damaged skin barrier structures, making it particularly beneficial for managing pressure ulcers and burn wounds. The comprehensive benefits it offers for various skin issues stem from its capacity to induce the regeneration of pathological and damaged skin tissue.

Pipeline

  • Five topical skincare products containing Repurinol with completed development.

  • Ongoing projects for the development of sun protection and anti-aging skincare products utilizing SMDRM technology

  • A candidate topical drug for pre-clinical and clinical studies

  • An ongoing project for the discovery of a new anti-cancer drug candidate using SMDRM technology